Download presentation
Presentation is loading. Please wait.
Published byMilo Quinn Modified over 9 years ago
1
Copyright © 2006 by Mosby, Inc. Slide 1 Section III The Therapist-Driven Protocol Program— The Essentials
2
Copyright © 2006 by Mosby, Inc. Slide 2 Chapter 9 The Therapist-Driven Protocol Program and the Role of the Respiratory Care Practitioner The Therapist-Driven Protocol Program and the Role of the Respiratory Care Practitioner
3
Copyright © 2006 by Mosby, Inc. Slide 3 Therapist-Driven Protocols (TDPs) Are an Integral Part of Respiratory Care Health Services
4
Copyright © 2006 by Mosby, Inc. Slide 4 The Purpose of TDPs Deliver individualized diagnostic and therapeutic respiratory to patients Assist the physician with evaluating patients’ respiratory care needs and to optimize the allocation of respiratory care services
5
Copyright © 2006 by Mosby, Inc. Slide 5 The Purpose of TDPs Determine the indications for respiratory therapy and the appropriate modalities for providing quality, cost-effective care that improves patient outcomes and decreases length of stay Empower respiratory care practitioners to allocate care using sign- and symptom-based algorithms for respiratory treatment
6
Copyright © 2006 by Mosby, Inc. Slide 6 Respiratory TDPs Give practitioner authority to: Gather clinical information related to the patient’s respiratory status Make an assessment of the clinical data collected Start, increase, decrease, or discontinue certain respiratory therapies on a moment- to-moment basis
7
Copyright © 2006 by Mosby, Inc. Slide 7 The Innate Beauty of Respiratory TDPs Is That: 1. The physician is always in the “information loop” regarding patient care 2. Therapy can be quickly modified in response to the specific and immediate needs of the patient
8
Copyright © 2006 by Mosby, Inc. Slide 8 Clinical Research Verifies These Facts Respiratory TDPs 1. Significantly improve respiratory therapy outcomes, and 2. Appreciably lower therapy costs
9
Copyright © 2006 by Mosby, Inc. Slide 9 Figure 9-1. The promise of a good TDP program.
10
Copyright © 2006 by Mosby, Inc. Slide 10 Figure 9-2. No Assessment Program in Place.
11
Copyright © 2006 by Mosby, Inc. Slide 11 The Knowledge Base Required for a Successful TDP Program The essential knowledge base includes the: Anatomic alterations of the lungs Pathophysiologic mechanisms activated Clinical manifestations that develop Treatment modalities used to correct the problem
12
Copyright © 2006 by Mosby, Inc. Slide 12 Figure 9-3. Foundations for a strong TDP program. Overview of the essential knowledge base for assessment of respiratory diseases.
13
Copyright © 2006 by Mosby, Inc. Slide 13 The Assessment Process Skills Required for a Successful TDP Program The practitioner must: Systematically gather clinical information Formulate an assessment Select an optimal treatment Document in a clear and precise manner
14
Copyright © 2006 by Mosby, Inc. Slide 14 Figure 9-4. The way knowledge, assessment, and a TDP program interface.
15
Copyright © 2006 by Mosby, Inc. Slide 15 Common Respiratory Assessments— Excerpts (see Table 9-1) Clinical DataAssessment WheezingBronchospasm RhonchiSecretions in large airways Weak coughPoor ability to mobilize secretions ABGsAcute ventilatory failure pH7.24 pH7.24 Pa CO 2 73 Pa CO 2 73 HCO 3 - 27 HCO 3 - 27 Pa O 2 53 Pa O 2 53
16
Copyright © 2006 by Mosby, Inc. Slide 16 Severity Assessment
17
Copyright © 2006 by Mosby, Inc. Slide 17 Table 9-2. Respiratory Care Protocol Severity Assessment— Excerpts Item0 point1 point2 points3 points4 pointsTotal Points Breath soundsClearBilateralBilateralBilateralAbsent and/or______ cracklescrackleswheezing,diminish & rhonchicrackles &bilateral and/or rhonchisevere wheezing, crackles, or rhonchi CoughStrong,ExcessiveExcessiveThickThick______ spontaneous,bronchialbronchialbronchialbronchial nonproductivesecretions &secretions butsecretions &secretions but strong coughweak coughweak coughno cough
18
Copyright © 2006 by Mosby, Inc. Slide 18 Severity Assessment Case Example SEVERITY ASSESSMENT CASE EXAMPLE A 67-YEAR-OLD-MALE ARRIVED IN THE EMERGENCY ROOM IN RESPIRATORY DISTRESS. THE PATIENT WAS WELL KNOWN TO THE TDP TEAM; HE HAD BEEN DIAGNOSED WITH CHRONIC BRONCHITIS SEVERAL YEARS BEFORE THIS ADMISSION (3 POINTS). THE PATIENT HAD NO RECENT SURGERY HISTORY, AND HE WAS AMBULATORY, ALERT, AND COOPERATIVE (0 POINTS). HE COMPLAINED OF DYSPNEA AND WAS USING HIS ACCESSORY MUSCLES OF INSPIRATION (3 POINTS). AUSCULTATION REVEALED BILATERAL RHONCHI OVER BOTH LUNG FIELDS (3 POINTS). HIS COUGH WAS WEAK AND PRODUCTIVE OF THICK GRAY SECRETIONS (3 POINTS). A CHEST RADIOGRAPH REVEALED PNEUMONIA (CONSOLIDATION) IN THE LEFT LOWER LUNG LOBE (3 POINTS). ON ROOM AIR HIS ARTERIAL BLOOD GAS VALUES WERE pH 7.52, Pa CO 2 54, HCO 3 - 41, AND Pa O 2 52—ACUTE ALVEOLAR HYPERVENTILATION ON CHRONIC VENTILATORY FAILURE (3 POINTS). USING THE SEVERITY ASSESSMENT FORM SHOWN IN TABLE 9-2, THE FOLLOWING TREATMENT SELECTION AND ADMINISTRATION FREQUENCY WOULD BE APPROPRIATE: TOTAL SCORE: 17 TREATMENT SELECTION: CHEST PHYSICAL THERAPY FREQUENCY OF ADMINISTRATION: FOUR TIMES A DAY; AS NEEDED
19
Copyright © 2006 by Mosby, Inc. Slide 19 The Top Four Respiratory Protocols Oxygen therapy protocol Bronchopulmonary hygiene therapy protocol Hyperinflation therapy protocol Aerosolized medication therapy protocol
20
Copyright © 2006 by Mosby, Inc. Slide 20 Common Respiratory Assessments and Treatment Plans—Excerpts (see Table 9-1) Clinical DataAssessmentTx Plan WheezingBronchospasmbeta 2 agent Rhonchi &Secretions in large airways Weak coughPoor ability to mobilize secretionsCPT ABGsAcute ventilatory failureMechanical ventilation pH7.24 pH7.24 Pa CO 2 73 Pa CO 2 73 HCO 3 - 27 HCO 3 - 27 Pa O 2 53 Pa O 2 53
21
Copyright © 2006 by Mosby, Inc. Slide 21 Oxygen Therapy Protocol 9-1
22
Copyright © 2006 by Mosby, Inc. Slide 22
23
Copyright © 2006 by Mosby, Inc. Slide 23
24
Copyright © 2006 by Mosby, Inc. Slide 24 Oxygen Therapy Protocol 9-1— Close-ups
25
Copyright © 2006 by Mosby, Inc. Slide 25
26
Copyright © 2006 by Mosby, Inc. Slide 26
27
Copyright © 2006 by Mosby, Inc. Slide 27
28
Copyright © 2006 by Mosby, Inc. Slide 28
29
Copyright © 2006 by Mosby, Inc. Slide 29 Common Oxygen Therapy Selections Nasal cannula Oxygen mask Venturi mask Partial rebreathing mask Nonrebreathing mask
30
Copyright © 2006 by Mosby, Inc. Slide 30 Bronchopulmonary Hygiene Therapy Protocol 9-2
31
Copyright © 2006 by Mosby, Inc. Slide 31
32
Copyright © 2006 by Mosby, Inc. Slide 32
33
Copyright © 2006 by Mosby, Inc. Slide 33 Bronchopulmonary Hygiene Therapy Protocol 9-2— Close-ups
34
Copyright © 2006 by Mosby, Inc. Slide 34
35
Copyright © 2006 by Mosby, Inc. Slide 35
36
Copyright © 2006 by Mosby, Inc. Slide 36
37
Copyright © 2006 by Mosby, Inc. Slide 37 Common Bronchopulmonary Hygiene Therapy Selections Increased fluid intake Cough and deep breathe Chest physical therapy Suctioning Bronchoscopy assist Mucolytic aerosol
38
Copyright © 2006 by Mosby, Inc. Slide 38 Hyperinflation Therapy Protocol 9-3 (Lung Expansion Protocol)
39
Copyright © 2006 by Mosby, Inc. Slide 39
40
Copyright © 2006 by Mosby, Inc. Slide 40
41
Copyright © 2006 by Mosby, Inc. Slide 41 Hyperinflation Therapy Protocol 9-3 (Lung Expansion Protocol)— Close-ups
42
Copyright © 2006 by Mosby, Inc. Slide 42
43
Copyright © 2006 by Mosby, Inc. Slide 43
44
Copyright © 2006 by Mosby, Inc. Slide 44
45
Copyright © 2006 by Mosby, Inc. Slide 45
46
Copyright © 2006 by Mosby, Inc. Slide 46 Common Hyperinflation Therapy Selections Cough and deep breathe Incentive spirometry IPPB CPAP PEEP PEEP
47
Copyright © 2006 by Mosby, Inc. Slide 47 Aerosolized Medication Therapy Protocol 9-4
48
Copyright © 2006 by Mosby, Inc. Slide 48
49
Copyright © 2006 by Mosby, Inc. Slide 49
50
Copyright © 2006 by Mosby, Inc. Slide 50 Aerosolized Medication Therapy Protocol 9-4— Close-ups
51
Copyright © 2006 by Mosby, Inc. Slide 51
52
Copyright © 2006 by Mosby, Inc. Slide 52
53
Copyright © 2006 by Mosby, Inc. Slide 53
54
Copyright © 2006 by Mosby, Inc. Slide 54 Common Aerosolized Medication Selections Bronchodilator agents Sympathomimetics Parasympatholytics Mucolytic agents Antiinflammatory agents Antibiotic agents
55
Copyright © 2006 by Mosby, Inc. Slide 55 Mechanical Ventilation Protocol 9-5
56
Copyright © 2006 by Mosby, Inc. Slide 56
57
Copyright © 2006 by Mosby, Inc. Slide 57
58
Copyright © 2006 by Mosby, Inc. Slide 58 Mechanical Ventilation Protocol 9-5— Close-ups
59
Copyright © 2006 by Mosby, Inc. Slide 59
60
Copyright © 2006 by Mosby, Inc. Slide 60
61
Copyright © 2006 by Mosby, Inc. Slide 61
62
Copyright © 2006 by Mosby, Inc. Slide 62
63
Copyright © 2006 by Mosby, Inc. Slide 63 Disorder: Normal Lung Mechanics but Patient Has Apnea Disease characteristics Normal compliance and airway resistance Ventilator mode Volume ventilation in the AC or SIMV mode Or pressure ventilation—either PRVC or PC Tidal volume and respiratory rate 10 to 12 ml/kg 6 to 10 bpm to 10 bpm when SIMV mode is used to 10 bpm when SIMV mode is used Table 9-3. Common Ventilatory Management Strategies
64
Copyright © 2006 by Mosby, Inc. Slide 64 Normal Lung Mechanics, cont. Flow rate 60 to 80 L/min I:E ratio 1:2 FI O 2 Low to moderate General goals and/or concerns Care to ensure plateau pressure of 30 cm H 2 O or less Smaller tidal volumes (<7 ml/kg) should be avoided because atelectasis can develop Table 9-3. Common Ventilatory Management Strategies, cont.
65
Copyright © 2006 by Mosby, Inc. Slide 65 Disorder: Chronic Obstructive Pulmonary Disease (COPD) Disease characteristics High lung compliance and high airway resistance Ventilator mode Volume ventilation in the AC or SIMV mode Or pressure ventilation—either PRVC or PC Noninvasive positive pressure ventilation (NPPV) is good alternative Tidal volume and respiratory rate Good starting point: 10 ml/kg and 10 to12 bpm A small tidal volume (8-10 ml/kg) and 8 to 10 bpm with increased flow rates to allow adequate expiratory time Table 9-3. Common Ventilatory Management Strategies, cont.
66
Copyright © 2006 by Mosby, Inc. Slide 66 COPD, cont. Flow rate 60 L/min I:E ratio 1:2 or 1:3 FI O 2 Low to moderate General goals and/or concerns Air-trapping and auto-PEEP can occur when expiratory time is too short ↑ Expiratory time to offset auto-PEEP May ↑ inspiratory flow up to 100 L/min to ↑ expiratory time May ↓ VT or rate to ↑ expiratory time Do not overventilate COPD patients with chronically high Pa CO 2 levels Table 9-3. Common Ventilatory Management Strategies, cont.
67
Copyright © 2006 by Mosby, Inc. Slide 67 Disorder: Acute Asthmatic Episode Disease characteristics High airway resistance Ventilator mode SIMV mode is recommended to offset air-trapping Tidal volume and respiratory rate Good starting point: 8 to 10 ml/kg Rate of 10 to 12 bpm When air-trapping is extensive, a lower tidal volume (5-6 ml/kg) and slower rate may be required Table 9-3. Common Ventilatory Management Strategies, cont.
68
Copyright © 2006 by Mosby, Inc. Slide 68 Acute Asthmatic Episode, cont. Flow rate 60 L/min I:E ratio 1:2 or 1:3 FI O 2 Start at 100% and titrate downward per Sp O 2 and ABGs General goals and/or concerns In severe cases, the development of auto-PEEP may be inevitable With controlled ventilation, a small amount of PEEP to offset auto-PEEP may be cautiously applied Table 9-3. Common Ventilatory Management Strategies, cont.
69
Copyright © 2006 by Mosby, Inc. Slide 69 Disorder: Acute Respiratory Distress Syndrome Disease characteristics Diffuse, uneven alveolar injury Ventilator mode Volume ventilation in the AC or SIMV mode Or pressure ventilation—PRVC or PC Tidal volume and respiratory rate Typically, started at low tidal volumes and higher rates 8 mL/kg and adjusted downward to 6 ml/kg; or 4 ml/kg 8 mL/kg and adjusted downward to 6 ml/kg; or 4 ml/kg Respiratory rate as high as 35 bpm Respiratory rate as high as 35 bpm Table 9-3. Common Ventilatory Management Strategies, cont.
70
Copyright © 2006 by Mosby, Inc. Slide 70 Acute Respiratory Distress Syndrome, cont. Flow rate 60 to 80 L/min I:E ratio 1:1 or 1:2 Do what is necessary to meet a rapid respiratory rate FI O 2 Less than 0.6 if possible General goals and/or concerns Goal is to limit transpulmonary pressures 30 cm H 2 O or less if possible PEEP is usually needed to prevent atelectasis Permissive hypercapnia may be allowed Table 9-3. Common Ventilatory Management Strategies, cont.
71
Copyright © 2006 by Mosby, Inc. Slide 71 Disorder: Postoperative Ventilatory Support Disease characteristics Often normal compliance and airway resistance Ventilator mode SIMV with pressure support Or AC volume ventilation Or pressure ventilation—either PRVC for PC Tidal volume and respiratory rate Good starting point: 10 to 12 ml/kg Rate of 10 to 12 bpm However, larger tidal volumes (12-15 ml/kg) and slower rates (6-10 bpm) may be used to maintain lung volume However, larger tidal volumes (12-15 ml/kg) and slower rates (6-10 bpm) may be used to maintain lung volume Table 9-3. Common Ventilatory Management Strategies, cont.
72
Copyright © 2006 by Mosby, Inc. Slide 72 Postoperative Ventilatory Support, cont. Flow rate 60 L/min I:E ratio 1:2 FI O 2 Low to moderate General goals and/or concerns PEEP or CPAP of 3 to 5 cm H 2 O may be applied to offset atelectasis Table 9-3. Common Ventilatory Management Strategies, cont.
73
Copyright © 2006 by Mosby, Inc. Slide 73 Disorder: Neuromuscular Disorder Disease characteristics Normal compliance and airway resistance Ventilator mode Volume ventilation in the AC or SIMV mode Or pressure ventilation—either PRVC or PC Tidal volume and respiratory rate Good starting point: 12 to 15 ml/kg Rate of 10 to 12 bpm Table 9-3. Common Ventilatory Management Strategies, cont.
74
Copyright © 2006 by Mosby, Inc. Slide 74 Neuromuscular Disorder, cont. Flow rate 60 L/min I:E ratio 1:2 FI O 2 Low to moderate General goals and/or concerns PEEP of 3 to 5 cm H 2 O may be applied to offset atelectasis Table 9-3. Common Ventilatory Management Strategies, cont.
75
Copyright © 2006 by Mosby, Inc. Slide 75 Overview Summary of a Good TDP Program
76
Copyright © 2006 by Mosby, Inc. Slide 76 Figure 9-5. Overview of the essential components of a good TDP program.
77
Copyright © 2006 by Mosby, Inc. Slide 77 Figure 9-5. Close-up.
78
Copyright © 2006 by Mosby, Inc. Slide 78 Figure 9-5. Close-up.
79
Copyright © 2006 by Mosby, Inc. Slide 79 Figure 9-5. Overview of the essential components of a good TDP program.
80
Copyright © 2006 by Mosby, Inc. Slide 80 Figure 9-6 Respiratory Care Protocol Program Assessment Form— Excerpts
81
Copyright © 2006 by Mosby, Inc. Slide 81 Oxygen Therapy Clinical Indicators History Sp O 2 <80% Pa O 2 <60 mm Hg Acute hypoxemia ↑ Respiratory rate ↑ Pulse Cyanosis Confusion Figure 9-6. Respiratory care protocol program assessment form—Example Excerpts
82
Copyright © 2006 by Mosby, Inc. Slide 82 Respiratory Assessment Examples Mild hypoxemia Moderate hypoxemia Severe hypoxemia Severity score: __________ Figure 9-6. Respiratory care protocol program assessment form—Example excerpts.
83
Copyright © 2006 by Mosby, Inc. Slide 83 Treatment Plan Oxygen Therapy Examples: Nasal cannula Oxygen mask 28% Venturi mask Frequency: _______________ Figure 9-6. Respiratory care protocol program assessment form—Example excerpts.
84
Copyright © 2006 by Mosby, Inc. Slide 84 Common Anatomic Alterations of the Lungs Atelectasis Alveolar consolidation ↑ Alveolar-capillary membrane thickness Bronchospasm Excessive bronchial secretions Distal airway and alveolar weakening
85
Copyright © 2006 by Mosby, Inc. Slide 85 Box 9-2. Pathophysiologic Mechanisms Commonly Activated in Respiratory Disorders Decreased V/Q ratio Alveolar diffusion block Decreased lung compliance Stimulation of oxygen receptors Deflation reflex Irritant reflex Pulmonary reflex Increased airway resistance Air-trapping and alveolar hyperinflation (See clinical scenarios.)
86
Copyright © 2006 by Mosby, Inc. Slide 86 Clinical Scenarios Activated by the Common Anatomic Alterations of the Lungs
87
Copyright © 2006 by Mosby, Inc. Slide 87 Atelectasis Clinical Scenario
88
Copyright © 2006 by Mosby, Inc. Slide 88 Figure 9-7. Atelectasis clinical scenario.
89
Copyright © 2006 by Mosby, Inc. Slide 89 Figure 9-7. Atelectasis—close-ups.
90
Copyright © 2006 by Mosby, Inc. Slide 90 Figure 9-7. Atelectasis clinical scenario—close-ups.
91
Copyright © 2006 by Mosby, Inc. Slide 91 Figure 9-7. Atelectasis clinical scenario—close-ups.
92
Copyright © 2006 by Mosby, Inc. Slide 92 Figure 9-7. Atelectasis clinical scenario—close-ups.
93
Copyright © 2006 by Mosby, Inc. Slide 93 Figure 9-7. Atelectasis clinical scenario—close-ups.
94
Copyright © 2006 by Mosby, Inc. Slide 94 Figure 9-7. Atelectasis clinical scenario.
95
Copyright © 2006 by Mosby, Inc. Slide 95 Alveolar Consolidation Clinical Scenario
96
Copyright © 2006 by Mosby, Inc. Slide 96 Figure 9-8. Alveolar consolidation clinical scenario.
97
Copyright © 2006 by Mosby, Inc. Slide 97 Figure 9-8. Alveolar consolidation clinical scenario (e.g., pneumonia)—close-ups.
98
Copyright © 2006 by Mosby, Inc. Slide 98 Figure 9-8. Alveolar consolidation clinical scenario—close-ups.
99
Copyright © 2006 by Mosby, Inc. Slide 99 Figure 9-8. Alveolar consolidation clinical scenario—close-ups.
100
Copyright © 2006 by Mosby, Inc. Slide 100 Figure 9-8. Alveolar consolidation clinical scenario—close-ups.
101
Copyright © 2006 by Mosby, Inc. Slide 101 Figure 9-8. Alveolar consolidation clinical scenario—close-ups.
102
Copyright © 2006 by Mosby, Inc. Slide 102 Figure 9-8. Alveolar consolidation clinical scenario.
103
Copyright © 2006 by Mosby, Inc. Slide 103 Increased Alveolar-Capillary Membrane Thickness Clinical Scenario
104
Copyright © 2006 by Mosby, Inc. Slide 104 Figure 9-9. Increased alveolar-capillary membrane thickness clinical scenario.
105
Copyright © 2006 by Mosby, Inc. Slide 105 Figure 9-9. Increased alveolar-capillary membrane thickness clinical scenario (e.g., ARDS)—close-ups.
106
Copyright © 2006 by Mosby, Inc. Slide 106 Figure 9-9. Increased alveolar-capillary membrane thickness clinical scenario—close-ups.
107
Copyright © 2006 by Mosby, Inc. Slide 107 Figure 9-9. Increased alveolar-capillary membrane thickness clinical scenario—close-ups.
108
Copyright © 2006 by Mosby, Inc. Slide 108 Figure 9-9. Increased alveolar-capillary membrane thickness clinical scenario—close-ups.
109
Copyright © 2006 by Mosby, Inc. Slide 109 Figure 9-9. Increased alveolar-capillary membrane thickness clinical scenario—close-ups.
110
Copyright © 2006 by Mosby, Inc. Slide 110 Figure 9-9. Increased alveolar-capillary membrane thickness clinical scenario.
111
Copyright © 2006 by Mosby, Inc. Slide 111 Bronchospasm Clinical Scenario
112
Copyright © 2006 by Mosby, Inc. Slide 112 Figure 9-10. Bronchospasm clinical scenario (e.g., asthma).
113
Copyright © 2006 by Mosby, Inc. Slide 113 Figure 9-10. Bronchospasm clinical scenario (e.g., asthma)—close-ups.
114
Copyright © 2006 by Mosby, Inc. Slide 114 Figure 9-10. Bronchospasm clinical scenario (e.g., asthma)—close-ups.
115
Copyright © 2006 by Mosby, Inc. Slide 115 Figure 9-10. Bronchospasm clinical scenario (e.g., asthma)—close-ups.
116
Copyright © 2006 by Mosby, Inc. Slide 116 Figure 9-10. Bronchospasm clinical scenario (e.g., asthma)—close-ups.
117
Copyright © 2006 by Mosby, Inc. Slide 117 Figure 9-10. Bronchospasm clinical scenario (e.g., asthma)—close-ups.
118
Copyright © 2006 by Mosby, Inc. Slide 118 Figure 9-10. Bronchospasm clinical scenario (e.g., asthma).
119
Copyright © 2006 by Mosby, Inc. Slide 119 Excessive Bronchial Secretions Clinical Scenario
120
Copyright © 2006 by Mosby, Inc. Slide 120 Figure 9-11. Excessive bronchial secretions clinical scenario.
121
Copyright © 2006 by Mosby, Inc. Slide 121 Figure 9-11. Excessive bronchial secretions clinical scenario—close-ups.
122
Copyright © 2006 by Mosby, Inc. Slide 122 Figure 9-11. Excessive bronchial secretions clinical scenario—close-ups.
123
Copyright © 2006 by Mosby, Inc. Slide 123 Figure 9-11. Excessive bronchial secretions clinical scenario—close-ups.
124
Copyright © 2006 by Mosby, Inc. Slide 124 Figure 9-11. Excessive bronchial secretions clinical scenario—close-ups.
125
Copyright © 2006 by Mosby, Inc. Slide 125 Figure 9-11. Excessive bronchial secretions clinical scenario—close-ups.
126
Copyright © 2006 by Mosby, Inc. Slide 126 Figure 9-11. Excessive bronchial secretions clinical scenario.
127
Copyright © 2006 by Mosby, Inc. Slide 127 Distal Airway and Alveolar Weakening Clinical Scenario
128
Copyright © 2006 by Mosby, Inc. Slide 128 Fig. 9-12 Distal airway and alveolar weakening clinical scenario.
129
Copyright © 2006 by Mosby, Inc. Slide 129 Figure 9-12. Distal airway and alveolar weakening clinical scenario—close-ups.
130
Copyright © 2006 by Mosby, Inc. Slide 130 Figure 9-12. Distal airway and alveolar weakening clinical scenario—close-ups.
131
Copyright © 2006 by Mosby, Inc. Slide 131 Figure 9-12. Distal airway and alveolar weakening clinical scenario—close-ups.
132
Copyright © 2006 by Mosby, Inc. Slide 132 Figure 9-12. Distal airway and alveolar weakening clinical scenario—close-ups.
133
Copyright © 2006 by Mosby, Inc. Slide 133 Figure 9-12. Distal airway and alveolar weakening clinical scenario—close-ups.
134
Copyright © 2006 by Mosby, Inc. Slide 134 Figure 9-12. Distal airway and alveolar weakening clinical scenario.
135
Copyright © 2006 by Mosby, Inc. Slide 135 Figure 9-13. A three-component model of a prototype airway. A, Airway lumen; B, airway wall; C, supporting structure.
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.